The Outcome of HyperCVAD Combined with Alemtuzumab for the Treatment of Aggressive T-Cell and NK-Cell Neoplasms.
We report our experience in using six cycles of hyperCVAD in combination with alemtuzumab for the treatment of aggressive T-cell and NK/T-cell neoplasms. Seven females and six males with the median age of 41 (range 18–60) diagnosed with T-cell acute lymphoblastic lymphoma and peripheral T-cell...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier Ltd.
2011
|
| Subjects: | |
| Online Access: | http://ir.unimas.my/id/eprint/12281/ http://ir.unimas.my/id/eprint/12281/7/A%20randomized%20double%20blind%20control%20trial%20comparing%20filgrastim%20%28abstract%29.pdf |
| _version_ | 1848837166674739200 |
|---|---|
| author | Kuan, Jew-Win Chang, Kian-Meng Lau, Ngee Siang Visalachy, Purushothaman Tan, Sen Mui Ong, Tee Chuan Su, Anselm-Ting |
| author_facet | Kuan, Jew-Win Chang, Kian-Meng Lau, Ngee Siang Visalachy, Purushothaman Tan, Sen Mui Ong, Tee Chuan Su, Anselm-Ting |
| author_sort | Kuan, Jew-Win |
| building | UNIMAS Institutional Repository |
| collection | Online Access |
| description | We report our experience in using six cycles of
hyperCVAD in combination with alemtuzumab for the
treatment of aggressive T-cell and NK/T-cell neoplasms.
Seven females and six males with the median age of 41
(range 18–60) diagnosed with T-cell acute lymphoblastic
lymphoma and peripheral T-cell and NK/T-cell neoplasms
(nPTCL = 6, nT-cell ALL = 3, nNK/T-cell neoplasms = 4) from
2006 to 2008 were treated with alemtuzumab–hyperCVAD
regimen. A total of nine patients (69%) responded to the
regimen, with seven achieved complete remission and two
achieved partial remission. The median progression free
survival and overall survival duration among the responders
with complete remission were 12.9 and 24.9 months
respectively. The incidence of relapse among the responders
was 44% and the overall survival rate was 23%. Only
four (31%) patients completed the six cycles of alemtuzumab–
hyperCVAD. Others were stopped earlier due to
progressive disease (n = 2), cytomegalovirus (CMV)
reactivation and/or disease (n = 3), death not due to disease (n = 2), and patient’s refusal to continue alemtuzumab (n = 2). The incidence of death not due to disease, CMV reactivation and recurrent CMV reactivation were 50, 50 and 17%, respectively. This study shows that alemtuzumab in combination with hyperCVAD regimen is a feasible regimen but with high toxicity. The toxicity might be reduced with the incorporation of filgrastim and use of
valganciclovir as CMV prophylaxis. |
| first_indexed | 2025-11-15T06:35:21Z |
| format | Article |
| id | unimas-12281 |
| institution | Universiti Malaysia Sarawak |
| institution_category | Local University |
| language | English |
| last_indexed | 2025-11-15T06:35:21Z |
| publishDate | 2011 |
| publisher | Elsevier Ltd. |
| recordtype | eprints |
| repository_type | Digital Repository |
| spelling | unimas-122812016-06-10T07:46:58Z http://ir.unimas.my/id/eprint/12281/ The Outcome of HyperCVAD Combined with Alemtuzumab for the Treatment of Aggressive T-Cell and NK-Cell Neoplasms. Kuan, Jew-Win Chang, Kian-Meng Lau, Ngee Siang Visalachy, Purushothaman Tan, Sen Mui Ong, Tee Chuan Su, Anselm-Ting RZ Other systems of medicine We report our experience in using six cycles of hyperCVAD in combination with alemtuzumab for the treatment of aggressive T-cell and NK/T-cell neoplasms. Seven females and six males with the median age of 41 (range 18–60) diagnosed with T-cell acute lymphoblastic lymphoma and peripheral T-cell and NK/T-cell neoplasms (nPTCL = 6, nT-cell ALL = 3, nNK/T-cell neoplasms = 4) from 2006 to 2008 were treated with alemtuzumab–hyperCVAD regimen. A total of nine patients (69%) responded to the regimen, with seven achieved complete remission and two achieved partial remission. The median progression free survival and overall survival duration among the responders with complete remission were 12.9 and 24.9 months respectively. The incidence of relapse among the responders was 44% and the overall survival rate was 23%. Only four (31%) patients completed the six cycles of alemtuzumab– hyperCVAD. Others were stopped earlier due to progressive disease (n = 2), cytomegalovirus (CMV) reactivation and/or disease (n = 3), death not due to disease (n = 2), and patient’s refusal to continue alemtuzumab (n = 2). The incidence of death not due to disease, CMV reactivation and recurrent CMV reactivation were 50, 50 and 17%, respectively. This study shows that alemtuzumab in combination with hyperCVAD regimen is a feasible regimen but with high toxicity. The toxicity might be reduced with the incorporation of filgrastim and use of valganciclovir as CMV prophylaxis. Elsevier Ltd. 2011 Article PeerReviewed text en http://ir.unimas.my/id/eprint/12281/7/A%20randomized%20double%20blind%20control%20trial%20comparing%20filgrastim%20%28abstract%29.pdf Kuan, Jew-Win and Chang, Kian-Meng and Lau, Ngee Siang and Visalachy, Purushothaman and Tan, Sen Mui and Ong, Tee Chuan and Su, Anselm-Ting (2011) The Outcome of HyperCVAD Combined with Alemtuzumab for the Treatment of Aggressive T-Cell and NK-Cell Neoplasms. Indian journal of hematology & blood transfusion, 27 (3). pp. 136-145. ISSN 1473-0502 http://dx.doi.org/10.1016/j.transci.2015.03.017 |
| spellingShingle | RZ Other systems of medicine Kuan, Jew-Win Chang, Kian-Meng Lau, Ngee Siang Visalachy, Purushothaman Tan, Sen Mui Ong, Tee Chuan Su, Anselm-Ting The Outcome of HyperCVAD Combined with Alemtuzumab for the Treatment of Aggressive T-Cell and NK-Cell Neoplasms. |
| title | The Outcome of HyperCVAD Combined with Alemtuzumab for the Treatment of Aggressive T-Cell and NK-Cell Neoplasms. |
| title_full | The Outcome of HyperCVAD Combined with Alemtuzumab for the Treatment of Aggressive T-Cell and NK-Cell Neoplasms. |
| title_fullStr | The Outcome of HyperCVAD Combined with Alemtuzumab for the Treatment of Aggressive T-Cell and NK-Cell Neoplasms. |
| title_full_unstemmed | The Outcome of HyperCVAD Combined with Alemtuzumab for the Treatment of Aggressive T-Cell and NK-Cell Neoplasms. |
| title_short | The Outcome of HyperCVAD Combined with Alemtuzumab for the Treatment of Aggressive T-Cell and NK-Cell Neoplasms. |
| title_sort | outcome of hypercvad combined with alemtuzumab for the treatment of aggressive t-cell and nk-cell neoplasms. |
| topic | RZ Other systems of medicine |
| url | http://ir.unimas.my/id/eprint/12281/ http://ir.unimas.my/id/eprint/12281/ http://ir.unimas.my/id/eprint/12281/7/A%20randomized%20double%20blind%20control%20trial%20comparing%20filgrastim%20%28abstract%29.pdf |